Brinker International, Inc.
$9.95B- Market cap
- $9.62B
- Debt
- +$448.00M
- Cash
- −$110.00M
Capital structure 96% equity / 4% debt · EV / Revenue 1.71x · EV / EBITDA 11.35x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: EAT stock price vs CTXR: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CTXR's multiple
Needs CTXR P/E.
Implied fair value · at EAT's multiple
Needs EPS (TTM) is negative, EAT P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: EAT FY 2026 (ended Jun 24, 2026) · CTXR FY 2022 (ended Sep 30, 2022). Fiscal years are not aligned.
Trendline
Nine fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 96% equity / 4% debt · EV / Revenue 1.71x · EV / EBITDA 11.35x
Capital structure 161% equity / -61% debt · EV / EBITDA 0.96x
EAT carries the larger enterprise value at $9.95B against -$31.69M; CTXR trades on the lower EV / EBITDA multiple (0.96x vs 11.35x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
BRINKER INTERNATIONAL, INC. · implied price per share
Bear
$106.35
Base
$126.42
Bull
$152.55
Citius Pharmaceuticals, Inc. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
1.01x
-0.06x
Net debt / EBITDA
Leverage against operating earnings
0.39x
1.45x
Cash and equivalents
Liquid reserves on the balance sheet
$110.00M
$41.71M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Bloomin' Brands, Inc.
EAT vs BLMN
DARDEN RESTAURANTS INC
EAT vs DRI
CRACKER BARREL OLD COUNTRY STORE, INC
EAT vs CBRL
Dave & Buster's Entertainment, Inc.
EAT vs PLAY
Zomedica Corp.
EAT vs ZOM
Aquestive Therapeutics, Inc.
EAT vs AQST
ACADIA PHARMACEUTICALS INC
EAT vs ACAD
AMGEN INC
EAT vs AMGN
GILEAD SCIENCES, INC.
EAT vs GILD
AbbVie Inc.
EAT vs ABBV
$448.00M
-$6.11M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.